News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
13th
Mar 17
Synairgen Collaboration Progress
Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to report progress from its ongoing collaboration with UK biotechnology company Synairgen plc (LSE: SNG) to develop a selective inhibitor to the lysyl oxidase-like 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis and other fibrotic conditions.
On Friday UK time Synairgen announced data from an in vivo preclinical model of lung fibrosis.
Refer to the Synairgen media release.
Read full media release - pdf